文献速递冠心病心力衰竭与心肌病心律失常

COVID-19 患者死亡结局的心血管意义

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19).
PubMed 文献 · JAMA Cardiol · 2020-01-01

该单中心回顾性病例系列纳入武汉第七医院 2020 年 1 月 23 日至 2 月 23 日确诊 COVID-19 患者 187 例,分析基础心血管病(CVD)与心肌损伤(肌钙蛋白 T 升高)和死亡的关系。结果显示心肌损伤与死亡显著相关,而仅有基础 CVD 无心肌损伤者预后相对较好。

要点

  • 合并基础 CVD 且 TnT 升高者住院死亡率 69.44%(25/36),显著高于其他组。
  • 无基础 CVD 且 TnT 正常者住院死亡率 7.62%(8/105)。
  • TnT 升高与恶性心律失常更多、糖皮质激素和机械通气使用率更高相关。

核心结论

  • 心肌损伤与 COVID-19 死亡结局显著相关,仅有基础 CVD 而无心肌损伤者预后相对较好。
  • 心肌损伤与心功能障碍和心律失常相关,炎症可能是心肌损伤的潜在机制。

研究设计与样本

  • 回顾性单中心病例系列,分析武汉第七医院 2020 年 1 月 23 日至 2 月 23 日确诊 COVID-19 患者 187 例。
  • 按有无基础 CVD 及有无 TnT 升高分组,收集人口学、实验室、合并症和治疗资料。

主要发现

  • 187 例中出院 144 例(77%),死亡 43 例(23%);平均(SD)年龄 58.50(14.66)岁。
  • 66 例(35.3%)有基础 CVD,52 例(27.8%)存在 TnT 升高提示的心肌损伤。
  • 住院死亡率:无 CVD 且 TnT 正常 7.62%(8/105),有 CVD 且 TnT 正常 13.33%(4/30),无 CVD 但 TnT 升高 37.50%(6/16),有 CVD 且 TnT 升高 69.44%(25/36)。
  • 有基础 CVD 者较无 CVD 者更易出现 TnT 升高(36[54.5%] vs 16[13.2%])。
  • 死亡患者住院期间及濒死前 TnT 和 NT-proBNP 较入院值显著升高(P=.001;P<.001),存活者无显著动态变化(P=.96;P=.16)。

关键数值与推荐

  • 心肌损伤定义为 TnT 水平升高。
  • 血浆 TnT 与 hs-CRP(β=0.530,P<.001)及 NT-proBNP(β=0.613,P<.001)呈显著正相关。
  • 使用 ACEI/ARB 者与未使用者死亡率分别为 36.8%(7/19)和 21.4%(36/168)(P=.13)。

临床怎么用

  • 对 COVID-19 患者应关注基础 CVD 和 TnT 水平,识别心肌损伤高危人群。
  • 心肌损伤患者可能需考虑更积极的治疗,但需结合整体病情判断。

局限性

  • 回顾性单中心病例系列,样本量有限,结果需多中心研究验证。
  • ACEI/ARB 使用与死亡率的关系未达统计学显著性,不能据此推断因果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Increasing numbers of confirmed cases and mortality rates of coronavirus disease 2019 (COVID-19) are occurring in several countries and continents. Information regarding the impact of cardiovascular complication on fatal outcome is scarce. OBJECTIVE: To evaluate the association of underlying cardiovascular disease (CVD) and myocardial injury with fatal outcomes in patients with COVID-19. DESIGN, SETTING, AND PARTICIPANTS: This retrospective single-center case series analyzed patients with COVID-19 at the Seventh Hospital of Wuhan City, China, from January 23, 2020, to February 23, 2020. Analysis began February 25, 2020. MAIN OUTCOMES AND MEASURES: Demographic data, laboratory findings, comorbidities, and treatments were collected and analyzed in patients with and without elevation of troponin T (TnT) levels. RESULTS: Among 187 patients with confirmed COVID-19, 144 patients (77%) were discharged and 43 patients (23%) died. The mean (SD) age was 58.50 (14.66) years. Overall, 66 (35.3%) had underlying CVD including hypertension, coronary heart disease, and cardiomyopathy, and 52 (27.8%) exhibited myocardial injury as indicated by elevated TnT levels. The mortality during hospitalization was 7.62% (8 of 105) for patients without underlying CVD and normal TnT levels, 13.33% (4 of 30) for those with underlying CVD and normal TnT levels, 37.50% (6 of 16) for those without underlying CVD but elevated TnT levels, and 69.44% (25 of 36) for those with underlying CVD and elevated TnTs. Patients with underlying CVD were more likely to exhibit elevation of TnT levels compared with the patients without CVD (36 [54.5%] vs 16 [13.2%]). Plasma TnT levels demonstrated a high and significantly positive linear correlation with plasma high-sensitivity C-reactive protein levels (β = 0.530, P < .001) and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels (β = 0.613, P < .001). Plasma TnT and NT-proBNP levels during hospitalization (median [interquartile range (IQR)], 0.307 [0.094-0.600]; 1902.00 [728.35-8100.00]) and impending death (median [IQR], 0.141 [0.058-0.860]; 5375 [1179.50-25695.25]) increased significantly compared with admission values (median [IQR], 0.0355 [0.015-0.102]; 796.90 [401.93-1742.25]) in patients who died (P = .001; P < .001), while no significant dynamic changes of TnT (median [IQR], 0.010 [0.007-0.019]; 0.013 [0.007-0.022]; 0.011 [0.007-0.016]) and NT-proBNP (median [IQR], 352.20 [174.70-636.70]; 433.80 [155.80-1272.60]; 145.40 [63.4-526.50]) was observed in survivors (P = .96; P = .16). During hospitalization, patients with elevated TnT levels had more frequent malignant arrhythmias, and the use of glucocorticoid therapy (37 [71.2%] vs 69 [51.1%]) and mechanical ventilation (31 [59.6%] vs 14 [10.4%]) were higher compared with patients with normal TnT levels. The mortality rates of patients with and without use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers was 36.8% (7 of 19) and 21.4% (36 of 168) (P = .13). CONCLUSIONS AND RELEVANCE: Myocardial injury is significantly associated with fatal outcome of COVID-19, while the prognosis of patients with underlying CVD but without myocardial injury is relatively favorable. Myocardial injury is associated with cardiac dysfunction and arrhythmias. Inflammation may be a potential mechanism for myocardial injury. Aggressive treatment may be considered for patients at high risk of myocardial injury.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020. PMID: 32219356. doi:10.1001/jamacardio.2020.1017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。